-transparent.png){kind=logo}
Since Jan. 1, 1976, nearly all new cases of testicular germ cell tumours have been included in the Danish Testicular Carcinoma Study (DATECA), and have been monitored by the tumour markers alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG). During the first five years, 1058 patients participated in the investigation, but only 603 of these patients were followed by preoperative as well as postoperative marker determinations in serum. The overall prevalence of marker positivity, i.e. elevated preoperative values for AFP and/or HCG, was 8 per cent for seminoma patients and 60 per cent for non-seminoma patients. Elevated levels of serum AFP and HCG were correlated to the presence of endodermal sinus tumour and choriocarcinoma elements, respectively, in the primary tumour. The presence of increased marker concentration in serum was correlated stage (higher percentage in higher stages) and to prognosis (marker negative patients had a better prognosis than marker positive patients). Marker production by seminoma patients seems to indicate a poor prognosis, especially for HCG producing seminomas.
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
January 1984,
Acta radiologica. Oncology,
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
January 1984,
Acta radiologica. Oncology,
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
January 1984,
Acta radiologica. Oncology,
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
March 1986,
British medical journal (Clinical research ed.),
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
January 1987,
Radiography,
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
May 1986,
British medical journal (Clinical research ed.),
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
March 2011,
Der Urologe. Ausg. A,
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
June 2004,
Histopathology,
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
January 1985,
Progress in clinical and biological research,
B Nørgaard-Pedersen, and
H P Schultz, and
J Arends, and
H Brincker, and
G Krag Jacobsen, and
B Lindeløv, and
M Rørth, and
I L Svennekjaer
March 2021,
Critical reviews in oncology/hematology,
